These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27090944)

  • 21. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.
    Wang Z; Zhao YT; Zhao TC
    Exp Biol Med (Maywood); 2021 Jan; 246(2):213-225. PubMed ID: 32727215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [EPIGENETIC ENZYMES AS THERAPEUTIC TARGETS FOR TREATING BRAIN DISORDERS].
    Gomazkov OA
    Eksp Klin Farmakol; 2015; 78(11):35-44. PubMed ID: 27017704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.
    Zhang S; Zhan L; Li X; Yang Z; Luo Y; Zhao H
    Int J Biol Sci; 2021; 17(13):3381-3400. PubMed ID: 34512154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer.
    Chiaradonna F; Cirulli C; Palorini R; Votta G; Alberghina L
    Antioxid Redox Signal; 2015 Jul; 23(1):30-50. PubMed ID: 24483782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylases and inhibitors in diabetes mellitus and its complications.
    Wang L; Bai Y; Cao Z; Guo Z; Lian Y; Liu P; Zeng Y; Lyu W; Chen Q
    Biomed Pharmacother; 2024 Aug; 177():117010. PubMed ID: 38941890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic regulation in bacterial infections: targeting histone deacetylases.
    Grabiec AM; Potempa J
    Crit Rev Microbiol; 2018 May; 44(3):336-350. PubMed ID: 28971711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.
    Ceccacci E; Minucci S
    Br J Cancer; 2016 Mar; 114(6):605-11. PubMed ID: 26908329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?
    Grayson DR; Kundakovic M; Sharma RP
    Mol Pharmacol; 2010 Feb; 77(2):126-35. PubMed ID: 19917878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic application of histone deacetylase inhibitors for stroke.
    Lv L; Tang YP; Han X; Wang X; Dong Q
    Cent Nerv Syst Agents Med Chem; 2011 Jun; 11(2):138-49. PubMed ID: 21521169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylases (HDACs) as therapeutic target for depressive disorders.
    Misztak P; Pańczyszyn-Trzewik P; Sowa-Kućma M
    Pharmacol Rep; 2018 Apr; 70(2):398-408. PubMed ID: 29456074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
    Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
    Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylases (HDAC) in physiological and pathological bone remodelling.
    Cantley MD; Zannettino ACW; Bartold PM; Fairlie DP; Haynes DR
    Bone; 2017 Feb; 95():162-174. PubMed ID: 27913271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
    Richardson PG; Mitsiades CS; Laubach JP; Hajek R; Spicka I; Dimopoulos MA; Moreau P; Siegel DS; Jagannath S; Anderson KC
    Leuk Res; 2013 Jul; 37(7):829-37. PubMed ID: 23582718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions.
    Royce SG; Karagiannis TC
    Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):44-8. PubMed ID: 24322009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered expression of histone deacetylases in cancer.
    Montezuma D; Henrique RM; Jerónimo C
    Crit Rev Oncog; 2015; 20(1-2):19-34. PubMed ID: 25746102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.